Skip to main content

Advertisement

Table 1 Baseline clinicopathologic characteristics in ALK-rearranged patients with advanced non-small-cell lung cancer treated with crizotinib

From: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Characteristic No. of Patients (%) P-value
ALK + c-Met-
(n = 101)
ALK + c-Met+
(n = 15)
 
Age, years
 Median 50 44 0.551
 Range 25–79 24–75  
Gender
 Male 45 (44.6%) 7(46.7%) 1.000
 Female 56(55.4%) 8(53.3%)  
ECOG PS
 0–1 88(84.9%) 15(100.0%) 0.213
  ≥ 2 13(15.1%) 0(0.0%)  
Smoking status
 Non-smoker 83(82.2%) 14(93.3%) 0.460
 Smoker 18(17.8%) 1(6.7%)  
Histology
 Adenocarcinoma 98(97.0%) 14(93.3%) 0.228
 Others 3(3.0%) 1(6.7%)  
Clinical staging
 IIIB 5(5.9%) 0(0.0%) 1.000
 IV 96(94.1%) 15(100.0%)  
Lines of crizotinib
 1st-line 52(51.5%) 7(46.7%) 0.787
 2nd-or further-lines 49(48.5%) 8(53.3%)  
  1. Abbreviations: ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, ALK + c-Met+ patients with ALK rearrangement and c-Met overexpression positive, ALK + c-Met- patients with ALK rearrangement and c-Met overexpression negative, ECOG PS Eastern Cooperative Oncology Group performance status. Cinical staging was classified based on American Joint Committee on Cancer 7th edition